

**Supplementary Table S2. Nonocular adverse events  
in ≥10% of study patients**

<i>Nonocular adverse events in ≥10% of study patients</i>	<i>Cohort 1 + 2, N = 6 (%)</i>	<i>Cohort 3 + 4, N = 15 (%)</i>
Blood and lymphatic system disorders		
Anemia	0 (0.0)	3 (20.0)
Gastrointestinal disorders		
Dyspepsia	1 (16.7)	0 (0.0)
Infections and infestations		
Acute sinusitis	1 (16.7)	0 (0.0)
Diverticulitis	1 (16.7)	0 (0.0)
Nasopharyngitis	1 (16.7)	1 (6.7)
Pneumonia	1 (16.7)	0 (0.0)
Respiratory tract infection	1 (16.7)	1 (6.7)
Urinary tract infection	1 (16.7)	2 (13.3)
Investigations		
Bacterial test positive	1 (16.7)	0 (0.0)
Blood potassium decreased	1 (16.7)	0 (0.0)
Blood pressure increased	1 (16.7)	0 (0.0)
Cells in urine	1 (16.7)	2 (13.3)
Eosinophil percentage increased	1 (16.7)	0 (0.0)
Hematocrit decreased	2 (33.3)	0 (0.0)
Hemoglobin decreased	2 (33.3)	1 (6.7)
Oxygen saturation decreased	1 (16.7)	0 (0.0)
Urine analysis abnormal	1 (16.7)	0 (0.0)
White blood cells urine positive	1 (16.7)	0 (0.0)
Musculoskeletal and connective tissue disorders		
Arthralgia	0 (0)	2 (13.3)
Back pain	0 (0)	2 (13.3)
Osteoarthritis	1 (16.7)	1 (6.7)
Neoplasms benign, malignant and unspecified (including cysts and polyps)		
Basal cell carcinoma	1 (16.7)	0 (0.0)
Intraductal proliferative breast lesion	1 (16.7)	0 (0.0)
Nervous system disorders		
Headache	0 (0)	2 (13.3)
Psychiatric disorders		
Hallucination	1 (16.7)	0 (0.0)
Renal and urinary disorders		
Urinary retention	1 (16.7)	0 (0.0)
Vascular disorders		
Hypertension	2 (33.3)	0 (0.0)